HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.

Abstract
Protein kinase inhibitors are a relatively new class of promising anticancer drugs, most of which exert their action by binding to the ATP site on the targeted kinases. We hypothesized that a decrease in ATP levels in neoplastic cells could reduce the competition for the same enzymatic site, thus increasing the efficacy of kinase inhibitors. Using oxamic acid, an inhibitor of lactic dehydrogenase (LDH) which hinders aerobic glycolysis, we decreased ATP levels in PLC/PRF/5 cells (a line from a hepatocellular carcinoma). We found that in these cells oxamic acid potentiated the antiproliferative activity of sorafenib, imatinib and sunitinib, three kinase inhibitors. When aerobic glycolysis was shut down by culturing the cells in the absence of glucose, oxamic acid did not reduce the ATP levels, suggesting that in normal tissues, which do not rely on aerobic glycolysis for their ATP synthesis, the block of LDH should not impair cellular metabolism. In conclusion, the inhibition of LDH could enhance anticancer activity of sorafenib, imatinib and sunitinib without increasing their side effects on normal cells, which in conditions of normal functional activity and sufficient oxygen supply do not need the activity of this enzyme.
AuthorsLuigi Fiume, Marina Vettraino, Marcella Manerba, Giuseppina Di Stefano
JournalPharmacological research (Pharmacol Res) Vol. 63 Issue 4 Pg. 328-34 (Apr 2011) ISSN: 1096-1186 [Electronic] Netherlands
PMID21168502 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Adenosine Triphosphate
  • Sorafenib
  • L-Lactate Dehydrogenase
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Oxamic Acid
  • Thymidine
Topics
  • Adenosine Triphosphate (metabolism)
  • Antineoplastic Agents (pharmacology)
  • Benzenesulfonates (pharmacology)
  • Carcinoma, Hepatocellular (drug therapy)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Drug Synergism
  • Glycolysis (drug effects)
  • Humans
  • L-Lactate Dehydrogenase (antagonists & inhibitors, metabolism)
  • Liver Neoplasms (drug therapy)
  • Mitogen-Activated Protein Kinase 1 (metabolism)
  • Mitogen-Activated Protein Kinase 3 (metabolism)
  • Niacinamide (analogs & derivatives)
  • Oxamic Acid (pharmacology)
  • Phenylurea Compounds
  • Protein Kinase Inhibitors (pharmacology)
  • Pyridines (pharmacology)
  • Sorafenib
  • Thymidine (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: